Eli Lilly to buy Merida Biosciences in a $2.9 billion immunology push

Eli Lilly is moving deeper into immunology and autoimmune drug development with an agreement to acquire Merida Biosciences, a company focused on therapies for immune-mediated diseases. The deal, reported at $2.9 billion, is positioned as Lilly’s latest step to broaden its portfolio through strategic acquisitions rather than relying only on internal pipeline development.

According to the report, Merida Biosciences develops autoimmune medicines, placing the target squarely in Lilly’s stated focus on immunology. The acquisition is being framed as a way to strengthen Lilly’s ability to compete in categories where demand is driven by chronic conditions and where large biopharma companies are racing to bring differentiated therapies to market.

While the purchase price was disclosed in the report, the post did not provide specific technical details about Merida’s lead assets, trial stage, or regulatory milestones, at least not in the information available here. It also did not spell out whether the agreement is all-cash, includes milestone payments, or how the company expects the acquisition to affect near-term earnings.

The size of the transaction indicates that Lilly views the immunology space as strategically important. Large acquisitions can be a way to accelerate access to novel targets, diversify a pipeline across multiple immune pathways, and reduce development risk relative to betting solely on early-stage discovery programs.

For Lilly, immunology has become a core battleground for long-term growth. Acquiring a specialist like Merida is also consistent with how many large drugmakers fill gaps in therapy areas where late-stage data, patient selection strategies, and biomarker-linked approaches can matter as much as the underlying biology.

Still, investors will be looking for clarity that was not included in the reported summary. Key items that typically accompany acquisitions, such as which product candidates are most material, expected timelines to pivotal trials, and any supply or manufacturing transition plans, were not detailed in the information available here.

The report also did not provide deal timing, including when the parties expect regulatory approvals or the closing date. It likewise did not mention whether Lilly is taking on specific collaboration obligations, licensing structures, or post-closing integration costs that could influence the overall economics of the transaction.

What to watch next is the company’s fuller disclosure of Merida’s pipeline and the binding terms of the agreement. A more detailed presentation of the acquisition targets, including clinical readouts and development plans, would help determine how the $2.9 billion purchase price maps to Lilly’s immunology roadmap.